Study of Rimonabant/Metformin Combinations to Investigate Diabetes (Blood Sugar) Control in Patients With Type 2 Diabetes
Status:
Withdrawn
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to demonstrate superiority of rimonabant/metformin
combinations in Glycosylated Hemoglobin 1c (A1C) reduction over the corresponding single
agent metformin and over rimonabant alone in patients with type 2 diabetes mellitus at 9
months.
The secondary objective is to investigate the effects of rimonabant/metformin combinations
for reducing fasted plasma glucose, body weight and triglycerides, and raising High Density
Lipoprotein Cholesterol (HDL-C) in comparison with metformin at 9 months.
Another objective is to evaluate the safety of rimonabant in combination with metformin over
a period of up to 52 weeks.